Tifeglipron for Type 2 Diabetes
A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 330 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
This trial is looking for adults with type 2 diabetes to test different doses of a medication called tifeglipron. Participants will help researchers understand how well this treatment works and how safe it is.
You may be able to join if
- I have been diagnosed with type 2 diabetes
- I have an HbA1c between 7% and 10.5%
- I manage my diabetes with diet and exercise or with metformin or SGLT-2 inhibitors
- My body mass index (BMI) is 23.0 or higher
- My weight has been stable for the last 3 months
You may not be able to join if
- I have type 1 diabetes or any other type of diabetes
- I have had severe low blood sugar or do not recognize low blood sugar symptoms in the last 6 months
- I have serious eye problems from diabetes that need emergency treatment
- I have significant kidney or nerve problems
- I have taken other diabetes medications in the last 3 months
- I have obesity caused by other hormone disorders
- I have known problems with stomach emptying
- I have poorly controlled high blood pressure
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Loading trial locations…
Reference Study ID Number: BP45703 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
CONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT